Compare Quest Diagnostics Inc (DGX) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs M&T Bank Corporation — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while M&T Bank Corporation trades at $242.05 (market cap $35.42B). The key difference: M&T Bank Corporation is the larger of the two by market cap, and M&T Bank Corporation pays the higher dividend (2.48%). Which is the better fit depends on your goals.
| DGX | MTB | |
|---|---|---|
Market Cap | $22.80B | $35.42B |
Sector | Health | Financials |
52-Week High | $216.02 | $242.55 |
52-Week Low | $166.42 | $178.63 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
M&T Bank Corporation (MTB) trades at $242.55, up 0.09% today, with a bullish technical signal supported by moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.18 exceeding expectations of $4.02. Revenue grew to $9.63B in 2025, with a net income margin of 29.59%. Recent news highlights Q2 2026 results announcement on July 15, 2026, with expectations of higher net interest income and loan growth.
Outlook remains positive due to strong profitability and dividend stability, but risks include elevated costs and net cash flow volatility. Analyst consensus is mixed with 29% buy ratings, though the price target of $242.72 suggests limited upside from current levels. Investors should weigh solid fundamentals against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
